摘要
目的:比较盐酸坦索罗辛缓释胶囊与盐酸坦洛新胶囊治疗前列腺炎的疗效和安全性。方法:在全部患者使用中成药宁泌泰胶囊的基础上,将160例Ⅲ型前列腺炎患者随机分为治疗组与对照组(各80例);治疗组给予盐酸坦索罗辛缓释胶囊,对照组则给予盐酸坦洛新胶囊,剂量均为0.2mg/qd,疗程为4周;患者治疗期间配合适当的性生活。对两组患者的疗效,慢性前列腺炎症状指数评分(NIH-CPSI)、疼痛症状评分(PS)、排尿症状评分(USS)、国际前列腺症状评分(IPSS)、生活质量评分(QLS)以及不良反应发生情况等指标进行统计。结果:治疗组总有效率为95%高于对照组的72.5%,其差异有统计学意义(P<0.05);组间比较NIH-CPSI评分、PS、USS、IPSS及QLS等指标均具有统计学意义(P<0.05)。结论:在联合应用宁泌泰胶囊的基础上,盐酸坦索罗辛缓释胶囊相比盐酸坦洛新胶囊在治疗Ⅲ型前列腺炎时安全有效且可靠性高。
Objectives： To investigate the clinical efficacy of tamsulosin combined with Ningbitai capsule in the treatment of type-Ⅲ prostatitis. Methods： 160 patients with type-Ⅲ prostatitis were randomly divided into treatment group and control group,with 80 cases in each group. The treatment group and control group were given imported tamsulosin capsule and domestic tamsulosin capsule 0. 2 mg/qd respectively,for 4 weeks. CP symptom score（ NIH-CPSI）,pain score（ PS）,voiding symptom score（ USS）,international prostate symptom score（ IPSS）,quality of life score（ QLS） and adverse events of the two groups were compared. Results： The treatment group had obviously higher efficacy and lithagogue rate than theses of control group,and the differences were statistically significant（ P 0. 05）. There were significant differences in NIH-CPSI value between pre-treatment and pro-treatment in both groups. NIH-CPSI,PS,USS,IPSS and QLS all had statistically significant difference（ P 0. 05）. Conclusion： Under the combination of Ningbitai capsule,the efficacy and safety of imported tamsulosin are much better than these of domestic tamsulosin in the treatment of type-Ⅲ prostatitis.
出处
《中国性科学》
2018年第1期14-17,共4页
Chinese Journal of Human Sexuality
